GLP-1 drugs enter trials to test impact on alcohol and drug cravings
GLP-1 drugs, first approved for diabetes and later for obesity, have sparked interest for broader therapeutic uses.
Researchers are now launching large clinical trials to evaluate whether these agents can reduce cravings for alcohol and other substances.
The studies aim to see if the appetite‑regulating and reward‑pathway effects of GLP-1 drugs can be leveraged to treat addiction, though results are not yet available.
This effort reflects a growing trend of repurposing metabolic medicines for neuropsychiatric conditions, with future adoption dependent on trial outcomes.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Big trials push beyond obesity to see if GLP-1s can quell alcohol, drug cravings”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that